A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF); LEVEL: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 18 to 85 years old - diagnosis of pulmonary arterial hypertension - on stable doses of heart medication for at least 30 days - there are specific requirements for birth control for women and men - see link to clinicaltrials.gov for complete inclusion & exclusion criteria

Exclusion Criteria:

- ability to walk is limited by anything other than symptoms (shortness of breath and fatigue) related to pulmonary hypertension - other diagnosis related to heart function such as valve disease, cardiomyopathy, etc. - current lung disease - study staff will review additional inclusion & exclusion criteria

Conditions & Interventions

Conditions:
Heart & Vascular, Rare Diseases
Keywords:
Clinics and Surgery Center (CSC), levosimendan, PH-HFpEF, pulmonary arterial hypertension, pulmonary vascular disease

More Information

Description: Levosimendan has not been approved by the FDA to treat people who have PH-HFpEF or approved to be taken by mouth (orally). In this study, we will measure the amount of levosimendan in blood at various times and evaluate the change in participants 6-Minute Walk Distance.
Study Contact: Thenappan Thenappan - tthenapp@umn.edu
Principal Investigator: Thenappan Thenappan
Phase: PHASE3
IRB Number: STUDY00020954